New imaging tracer could spot hidden cancers

NCT ID NCT07671092

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help doctors better detect and monitor these cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
RYZ211 (68Ga-RAYZ-2453) and RYZ212 (177Lu-RAYZ-2453) imaging agents
What this could lead to
If successful, this could lead to better imaging methods to detect and monitor certain metastatic cancers, helping doctors see where the cancer is in the body.
What could go wrong
This is a very early (phase 0) imaging study with only 40 participants. It is not designed to treat cancer, so it may not lead to any direct benefit for patients. The imaging agents involve radiation, which carries some risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Facility

    Christchurch, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.